ASTELLAS PHARMA INC by Astellas Pharma, Inc. Financials - Benzinga

ASTELLAS PHARMA INC by Astellas Pharma, Inc.

ALPMFOTCPK

Trade with Public

Trade with Public

$15.93

0.624.05%

At close: Sep 23, 5:00 PM EST

Overview NewsFinancialsSentiment Compare

ASTELLAS PHARMA INC by Astellas Pharma, Inc. Financials

ASTELLAS PHARMA INC by Astellas Pharma, Inc. (ALPMF) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

These Analysts Boost Their Forecasts On Vir Biotechnology

Avi Kapoor

Vir Biotechnology Stock Hits 52-Week High Tuesday - Here's Why

Vir Biotechnology stock skyrockets after $335 million Astellas deal, strong prostate cancer data, and upbeat earnings boost outlook.

Vandana Singh

Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data

Nuvation Bio halts its NUV-868 BET inhibitor program after Phase 1 study analysis. The decision impacts solid tumor treatments in ovarian, pancreatic, and mCRPC cancers, focusing instead on late-stage pipeline developments.

Vandana Singh

AbbVie Walks Away From CytomX Partnership, But Garnering Attention Of Big Pharma Partners

Vandana Singh

The Daily Biotech Pulse: Kezar Life Surges On Positive Kidney Disease Trial Data, FDA Rejects Spero Therapeutics' Tebipenem, Graybug Reviews Strategic Alternatives

Here's a roundup of top developments in the biotech space over the last 24 hours:

Vandana Singh